Related Experiment Video
Updated: Jul 4, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
[Study of inhibition effect of bovine lactoferrin in vitro on hepatitis B surface antigen]
Songtao Li1, Guirong Huang, Haibo Zhou
1Key Laboratory of Dairy Science, Ministry of Education, College of Food Science, Northeast Agricultural University, Harbin 150030, China. lisongtaoklds@126.com
Objective:
To probe inhibition effect of bovine lactoferrin (BLF) in vitro on hepatitis B surface antigen (HBsAg).
Methods:
Nature hepatitis B virus (HBV) was used to infect HepG2 cell, HBsAg in the culture supernatant was measured by ELISA, and MTT test was used to examine cytotoxic effect of BLF.
Results:
The maximum nontoxic dose (TD0) in HepG2 cell of BLF was 3.0 g/L,50% of toxic dose (TD50) was 11.08 g/L. After HepG2 cell were infected with HBV, every BLF test group had effect on inhibiting HBsAg to some extent. At the highest concentration of 3.0 g/L BLF was most effective, exhibiting 58.34% of inhibition. Mixing BLF with HBV, then HepG2 cell were infected with them, every BLF all test concentrations were not shown to inhibit HBsAg. Adding BLF to HepG2 cell, then HepG2 cell were infected with HBV after washing BLF, test groups were shown to significantly inhibite HBsAg as concentration of over 0.5 g/L BLF, but at the concentration 0.1 g/L of BLF inhibitious of HBsAg were not observed. HBsAg wasn't inhibited by lactoferrin hydrolysate.
Conclusion:
BLF was shown to inhibit HBV infection into HepG2 cell by protecting corresponding cell sites rather than binding to HBV. After HepG2 cell was infected, HBsAg also could be inhibited by BLF and lactoferrin hydrolysate didn't have this function. It was seemed that BLF could have structure's work, but the possible mechanism need to be lucubrated.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:25"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019